Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

00 p.m. Pacific Time with management to discuss results from the meeting as well as financial results for the first quarter and provide a general corporate update.

About Anthera PharmaceuticalsAnthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases.  Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy, or IgAN, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2013.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... ANGELES , Aug. 29, 2014  Chuma ... both financing alternatives and turnkey support services for ... announce that FINRA processed and approved the Company,s ... 29, 2014, CannaMed Corporation will be known as ... change was accomplished through a merger with the ...
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... 2014 Pomerantz LLP has filed a class ... (NASDAQ: EDAP ) and certain of its ... Court, Southern District of New York ... a class consisting of all persons or entities who ... 30, 2014, inclusive (the "Class Period"). This class action seeks ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Inc. (pronounced dot decimal), an innovative manufacturer of patient-specific ... 510(k) clearance from the FDA to market electron apertures ... now available to radiation oncology centers across the U.S. ... known as electron ,cutouts, by radiation therapy departments -- ...
... - Digital issue looks inside the minds, lives ... Journal of Emergency Medical Services ( JEMS ) ... issue featuring first-person accounts of responders who were thrust into ... terrorists invaded their response districts - and their lives - ...
Cached Medicine Technology:Florida Medical Device Manufacturer Announces New Product Release for Radiation Therapy 2Out of the Darkness 2Out of the Darkness 3
(Date:9/1/2014)... The Outlier Series announced the next ... content from one of the exceptional women featured in ... Game Changers . The title of the upcoming mini ... Jenny McClendon . McClendon is currently a full-time physician’s ... star of WeTV show, Raising Sextuplets. , Jenny was ...
(Date:9/1/2014)... Psychogenic Non-epileptic Seizures (PNES), also known as non-epileptic ... have devastating effects on those who develop it. These ... are not produced by electrical anomalies in the brain ... that the numbers of persons suffering PNES may be ... , Dr. Lorna Myers, Director of the Northeast Regional ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 The FDA ... Nutrition Facts label. If adopted, the proposed changes would ... addition of “added sugars” on the label, and a ... to keep “added sugars” off the label. NutriGold fully ... consumers make healthier food choices. “After 20 years, it's ...
(Date:8/31/2014)... Mesa, AZ (PRWEB) August 31, 2014 ... in Mesa, Arizona, prescribes sublingual immunotherapy to help his ... includes tree nut allergies. Dr. Agren said that it ... nut-based foods and, in many cases, restored peace of ... can lead to a host of symptoms, including rashes, ...
(Date:8/31/2014)... Orem, UT (PRWEB) August 31, 2014 ... a number of states have proposed legislation to require ... so consumers can make informed purchasing decisions that affect ... As an industry leader advocating for stringent measures to ... launch of its “Information, Communication, Engagement” (I.C.E.) initiative with ...
Breaking Medicine News(10 mins):Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 2Health News:Upcoming Outlier Series eBook about Jenny McClendon, PA-C, Former Start of Raising Sextuplets 3Health News:The Northeast Regional Epilepsy Group (NEREG) Offers First Conference on Psychogenic Non-epileptic Seizures (PNES) on September 20, 2014 in New Jersey 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 2Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 3Health News:NutriGold Supports the FDA's Call for an Updated Nutrition Facts Label 4Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 3Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... Annual Scientific Meeting: Nearly 5,300 physicians, scientists and ... IR" showcases the exciting ways that interventional radiologists ... on new research related to multiple sclerosis and ... From Science to Practice." There will be debates ...
... Feb. 9 (HealthDay News) -- Zebras evolved from all ... distract them from feeding, a new study contends. ... black and white stripes are the least-attractive hide pattern ... horseflies. The researchers found that horseflies are drawn ...
... a study to be presented today at the Society ... in Dallas, Texas, researchers will report findings that women ... appear to know little about the risks and benefits ... of labor to attempt a vaginal delivery, and that ...
... including the mapping of the genomes of more than ... base pairs of sequence data. The leading scientific journal ... the scientific breakthroughs of 2011. Large-scale genome sequencing is ... agricultural research. Henry Yang, Executive Managemer of BGI, ...
... WEDNESDAY, Feb. 8 (HealthDay News) -- Middle-school kids who participate ... than other kids, new research finds. Yet, students with ... apparent influence of peers is more pronounced among girls. ... smoking behavior of others even though there might be a ...
... Researchers at Virginia Commonwealth University Medical Center,s VCU ... Center (Richmond, VA) and Old Dominion University (Norfolk, ... 1 protein (WT1) results in downregulation of CD97 ... reduces the characteristic invasiveness exhibited by glial tumor ...
Cached Medicine News:Health News:Media alert: Society of Interventional Radiology's 37th Annual Scientific Meeting 2Health News:Bug Bites May Have Caused Zebras' Stripes 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 2Health News:VIB and BGI organize joint genomics meeting, Feb. 15, 2012, Belgium 3Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 2Health News:CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: